Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

BACKGROUND: EGFR T790M is the most common mutation associated with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Baseline EGFR T790M mutations in EGFR TKI-naïve patients have been reported, but the frequency and their association with response to EGFR TKIs remain unclear. PATIENTS A...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yu, H. A., Arcila, M. E., Hellmann, M. D., Kris, M. G., Ladanyi, M., Riely, G. J.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2014
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3905781/
https://ncbi.nlm.nih.gov/pubmed/24478319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt573
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares